pERK/pAkt phenotyping in circulating tumor cells as a biomarker for sorafenib efficacy in patients with advanced hepatocellular carcinoma

Sorafenib is a multikinase inhibitor approved for the treatment of advanced hepatocellular carcinoma (HCC). However, therapeutic response to sorafenib was not equal among HCC patients. Here we present a novel system to provide quantitative information concerning sorafenib-related targets by simultan...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncotarget
Hauptverfasser: Li, Jun, Shi, Lehua, Zhang, Xiaofeng, Sun, Bin, Yang, Yefa, Ge, Naijian, Liu, Huiying, Yang, Xia, Chen, Lei, Qian, Haihua, Wu, Mengchao, Yin, Zhengfeng
Format: Artigo
Sprache:Inglês
Veröffentlicht: Impact Journals LLC 2015
Schlagworte:
Research Paper
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4823061/
https://ncbi.nlm.nih.gov/pubmed/26544731
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.6104
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge